-

KARL STORZ and Saphena Medical to Provide Integrated Solutions for EVH Procedures

Innovative Products Promote Effective Clinical Care and Reduce Overall Costs

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ Endoscopy-America, Inc., a leader in minimally invasive surgical technology, is pleased to announce a new partnership with Saphena Medical to provide advanced instruments for endoscopic vessel harvesting (EVH).

EVH is a revolutionary procedure that enables surgeons to obtain grafts for coronary bypass using a keyhole approach, without lengthy incisions. Dr. Albert Chin, cofounder of Saphena, pioneered the technology, which has enjoyed rapid and widespread adoption in the field. The introduction of Saphena’s Venapax® device represented a major advance by enabling the surgeon to dissect, ligate, and extract a vessel with a single instrument.

The 4th generation Venapax has been specifically constructed with a reinforced shaft and internal guides to fit a KARL STORZ telescope. It allows for simplified radial artery or saphenous vein harvesting with a shortened learning curve and a drastically reduced overall disposable cost. The partnership began with a pilot program at five hospitals and will continue to expand on a phased basis.

“We are excited to join forces with such a dynamic and innovative partner. Our expertise in endoscopic imaging—which includes considerable experience in the cardiothoracic market—makes us the logical choice for advancing this EVH technology,” said Monica Ambrose, Executive Director of Surgical Marketing at KARL STORZ.

KARL STORZ Endoscopy-America, Inc., is an affiliate of KARL STORZ SE & Co. KG, an international leader for 75 years in reusable endoscope technology, providing surgical and procedural imaging, instrumentation, and enterprise-wide integration. Based in Tuttlingen, Germany, KARL STORZ SE & Co. KG is a family-owned company that designs, engineers, manufactures, and markets all its products with an emphasis on visionary design, precision craftsmanship, and clinical effectiveness. For more information, call (800) 421-0837 or visit the company’s website at www.karlstorz.com.

Contacts

Susan Jaffy Marx
Marketing Communications
KARL STORZ Endoscopy-America, Inc.
(424) 218-8701

KARL STORZ Endoscopy-America, Inc.


Release Versions

Contacts

Susan Jaffy Marx
Marketing Communications
KARL STORZ Endoscopy-America, Inc.
(424) 218-8701

More News From KARL STORZ Endoscopy-America, Inc.

ADDING MULTIMEDIA KARL STORZ Announces FDA Clearance for ENDOFLATOR + Insufflator and Smoke Evacuation System

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ, a global leader in minimally invasive surgical technology, is proud to announce it has received U.S. Food and Drug Administration (FDA) clearance for the ENDOFLATOR™ +. ENDOFLATOR + is the next-generation insufflator with integrated surgical smoke evacuation system designed to meet the evolving needs of modern operating rooms. Using carbon dioxide gas, an insufflator establishes and maintains a stable working cavity within the body during laparos...

KARL STORZ Unifies Canada, US, and Veterinary Organizations to Form North America Region Led by Sonal Matai

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ, a family-owned medical technology company headquartered in Tuttlingen, Germany, today announced the creation of a North America region that unifies its US, Canada, and Veterinary businesses under the leadership of Sonal Matai. Matai joined KARL STORZ in 2022 and was appointed to lead KARL STORZ United States in early 2024. As President of North America, Matai will now oversee key functions such as commercial operations, research and development,...

AventaMed, a KARL STORZ Company, Receives Expanded Indication for Solo+ Tympanostomy Tube Device (TTD)

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ United States is proud to announce that the US Food and Drug Administration (FDA) has cleared an expanded indication for the AventaMed Solo+™ Tympanostomy Tube Device (TTD), allowing its use in pediatric patients aged 6 months and older. This expanded clearance builds on the previous 510(k) clearance, which was indicated for patients 6 to 24 months old. The Solo+ device represents a significant advancement in pediatric ENT care. It is intended to...
Back to Newsroom